iPS cells hold great promise for new medical modalities. However, large-scale manufacturing of iPS cells is costly and labor intensive. To achieve widespread adoption, automation of the manufacturing process is essential to reduce the cost of iPS cells. Taiwan is a global leader in automated precision equipment manufacturing, especially in the semiconductor industry.
By combining Taiwan’s strengths in semiconductor technology with the CiRA Foundation’s medical research, this partnership will be a solution to bring iPS cell therapy from basic research to industrialization. By leveraging process optimization and cost reduction to provide high quality iPS cells, we will help make iPS cells into affordable medical products for the general population. We are also working toward the “ONE HEALTH” strategy of promoting human and animal health and maintaining and improving the ecological environment.